Trials / Terminated
TerminatedNCT01111448
Temsirolimus in Myelodysplastic Syndrome (MDS)
Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this Pilot-study is to evaluate the response of unselected MDS patients to temsirolimus a drug approved for the treatment of renal cell cancer. It is planned to give temsirolimus at a weekly dose of 25 mg as intravenous infusion for a maximum duration of 12 months. Regular bone marrow biopsies are planned for controlling MDS response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temsirolimus | 25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2013-06-01
- Completion
- 2014-06-01
- First posted
- 2010-04-27
- Last updated
- 2015-02-13
Locations
7 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01111448. Inclusion in this directory is not an endorsement.